NorthWest Biotherapeutics Inc (NWBO)

[TopelRoad]

Marnix B 2018 ASCO (posted from Senti):

"The timing to unblind the trial… you saw all those patients that are still alive… we have to wait to see how they do before we unblind. So that’s my final conclusion here. That the timing to unblind the trial will be dependent upon the rate of accumulation of events. If patients continue to live, the temptation to unblind is great, and the pressure to do it is huge. But it could be a terrible mistake. So we’re going to be very, very careful and deliberate in making that decision."


NWBO spoke about extended survival after patients cross a 36 month threshold, but that may not translate to trial completion. Data collection may continue until a rate of events is reached. I certainly hope ~36 months triggers some sort of data review. GLTA